Protagonist Therapeutics Inc - Asset Resilience Ratio
Protagonist Therapeutics Inc (PTGX) has an Asset Resilience Ratio of 65.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Protagonist Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Protagonist Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Protagonist Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Protagonist Therapeutics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $462.40 Million | 65.9% |
| Total Liquid Assets | $462.40 Million | 65.90% |
Asset Resilience Insights
- Very High Liquidity: Protagonist Therapeutics Inc maintains exceptional liquid asset reserves at 65.90% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Protagonist Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Protagonist Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Protagonist Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.19% | $321.66 Million | $744.73 Million | -0.08pp |
| 2023-12-31 | 43.27% | $154.89 Million | $357.95 Million | -1.75pp |
| 2022-12-31 | 45.02% | $111.61 Million | $247.93 Million | -13.43pp |
| 2021-12-31 | 58.45% | $203.24 Million | $347.69 Million | +0.37pp |
| 2020-12-31 | 58.08% | $188.45 Million | $324.47 Million | -6.48pp |
| 2019-12-31 | 64.56% | $100.01 Million | $154.92 Million | +31.13pp |
| 2018-12-31 | 33.43% | $46.62 Million | $139.47 Million | +10.23pp |
| 2017-12-31 | 23.19% | $37.97 Million | $163.73 Million | -36.94pp |
| 2016-12-31 | 60.13% | $56.52 Million | $93.99 Million | +7.13pp |
| 2015-12-31 | 53.00% | $7.87 Million | $14.85 Million | +52.90pp |
| 2014-12-31 | 0.10% | $10.00K | $10.33 Million | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more